PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21327909-0	2011	Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.	repaglinide	81-92	solute carrier organic anion transporter family member 1B1	Homo sapiens	11-18	
21327909-2	2011	The objective of this research was to study the effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.	repaglinide	129-140	solute carrier organic anion transporter family member 1B1	Homo sapiens	59-66	
21327909-9	2011	CONCLUSIONS: SLCO1B1*1B/*1B genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC(0- ) and increased clearance of repaglinide.	repaglinide	137-148	solute carrier organic anion transporter family member 1B1	Homo sapiens	13-20	
21327909-9	2011	CONCLUSIONS: SLCO1B1*1B/*1B genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC(0- ) and increased clearance of repaglinide.	repaglinide	206-217	solute carrier organic anion transporter family member 1B1	Homo sapiens	13-20	
21327909-10	2011	Moreover, this polymorphism of SLCO1B1 has significant influence on the pharmacokinetics of repaglinide, but no effects on its pharmacodynamics.	repaglinide	92-103	solute carrier organic anion transporter family member 1B1	Homo sapiens	31-38